Sinopharm : ANNOUNCEMENT PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD) FOR THE THREE MONTHS ENDED 31 MARCH 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)

(Stock Code: 01099)

ANNOUNCEMENT

PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD)

FOR THE THREE MONTHS ENDED 31 MARCH 2021

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the "Company") dated 23 April 2021 (the "Announcement") in relation to the first quarterly report for the three months ended

31 March 2021 (the "Reporting Period") of China National Medicines Corporation Ltd. ("SINOPHARM (CNCM LTD)"), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange

(stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of SINOPHARM (CNCM LTD) for the three months ended 31 March 2021 as set out in the Announcement.

1

PRINCIPAL FINANCIAL DATA OF SINOPHARM (CNCM LTD)

	As at the end of this
	Reporting Period
Total assets	24,667,366,766.59
Net assets attributable to
shareholder of listed	11,736,297,903.42
company

From the beginning of the year to the end of the Reporting Period

	Unit: Yuan
	Currency: RMB
	Increase/decrease at
	the end of this
Last year-end	Reporting Period as
	compared with last
	year-end (%)
24,904,932,990.82	-0.95
11,443,638,059.13	2.56
From the beginning of	Increase/decrease as
last year to the end of	compared with the
the reporting period of	same period of last
the last year	year (%)

Net cash flow arising from operating activities

Revenue

Net profit attributable to shareholders of the listed company

Net profit attributable to shareholders of the listed company after deducting non- recurring gains and losses

-1,202,178,079.00

From the beginning of the year to the end of the Reporting Period

10,346,847,263.05

297,809,564.48

291,764,304.58

-1,147,897,586.80	N/A
From the beginning of	Increase/decrease as
last year to the end of	compared with the
the reporting period of	same period of last
the last year	year (%)
8,209,804,658.59	26.03
231,972,537.64	28.38
193,681,077.30	50.64

Weighted average	2.57%
return on net assets (%)
Basic earnings per	0.3947
share (Yuan/Share)
Diluted earnings per	0.3947
share (Yuan/Share)

2.18%	increased by 0.39
percentage point
0.3075	28.36
0.3075	28.36

2

By order of the Board

Sinopharm Group Co. Ltd.

Yu Qingming

Chairman

Shanghai, the PRC

23 April 2021

As at the date of this announcement, the executive directors of the Company are Mr. Yu Qingming and Mr. Liu Yong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Ma Ping, Mr. Hu Jianwei, Mr. Deng Jindong, Mr. Wen Deyong, Ms. Guan Xiaohui and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Zhuo Fumin, Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung and Mr. Yu Weifeng.

• The Company is registered as a non-Hong Kong company under the Hong Kong Companies
  Ordinance under its Chinese name and the English name "Sinopharm Group Co. Ltd.".

3